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Intracranial hemorrhage (ICH) is a common complication in acute myeloid leukemia (AML)
patients with an incidence rate of 6.3% (1). Bleeding disorders related to disseminated
intravascular coagulation (DIC) are common complications in AML cases (2). Recombinant
activated FactorVII [rFVIIa (NovoSeven®)] is approved for the treatment of bleeding compli-
cations with FVIII or FIX inhibitors in patients with congenital FVII deficiency. Use of rFVIIa
for the treatment of acute hemorrhage in patients without hemophilia has been successful
(3, 4). Herein, we describe the successful use of rFVIIa in a patient with acute ICH in the
setting of newly diagnosed AML.
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A 26-year-old man without prior personal or family history of
bleeding disorders who had recently returned from serving in the
National Guard in Afghanistan presented with a sore throat, ecchy-
moses on his shin and thigh, and tongue petechiae. Infectious
disease workup was negative. However, complete blood count
revealed a white blood cell count of 300,000/µL, and the patient
treatment was initiated with hydroxyurea. Upon transfer to our
institution for further management, his white blood cell count
was 169,800/µL, hemoglobin was 6.8 g/dL, and platelet count
was 21,000/µl. The peripheral blood smear was consistent with
acute myeloid leukemia (AML), and he was initiated on cytarabine
and hydroxyurea. The work up for acute promyelocytic leukemia
(APL) including PML-RARA fusion transcript analysis by qualita-
tive reverse-transcription polymerase chain reaction was negative
and cytogenetics revealed 46 XY, t (9;11) (p22;q23).
The patient concomitantly experienced intermittent headaches
at presentation. Neuroimaging demonstrated acute multi-focal
intra-cerebral hemorrhages. The clinical course, the progression
of intra-cerebral hemorrhages, and supportive treatments were
summarized (Figure 1).
The laboratory evaluation were consistent with DIC: throm-
bocytopenia (platelet count, 21,000/µL), prolonged prothrom-
bin time (17.7 s), elevated activated partial thromboplastin time
(37.4 s), decreased fibrinogen level (184 mg/dL), and an elevated
D-dimer (>20µg/mL). Over the next several days the patient
received several units of blood products including 20 units cryo-
precipitate, 12 units of fresh frozen plasma, and 48 units of pooled
platelet. However, the patient became increasingly somnolent and
experienced progressive left-sided weakness. A repeat of neu-
roimaging revealed increase in the size of his right intra-cerebral
hemorrhage (Figure 2). Progression of the patient’s intracranial
hemorrhage (ICH) in spite of frequent transfusions with blood
products, prompted initiation of treatment with continuous intra-
venous infusion of aminocaproic acid (1 g/h) and one dose of
rFVIIa (20µg/kg). Within 1 day after infusion of rFVIIa, his ICH
stabilized as was evident in his follow-up brain imaging. The
patient clinically improved over the subsequent few days with an
eventual complete neurologic recovery.
Finalized bone marrow evaluation of the patient revealed a
diagnosis of AML-M5 with t (9;11) translocation and a FLT3-
ITD mutation. After undergoing induction chemotherapy with
idarubicin, cytarabine, and sorafenib and two subsequent cycles
of consolidation chemotherapy, he achieved complete morpho-
logical remission and had no evidence of molecular minimal
residual disease by multiplanar flow-cytometry. Due to the nature
of his high risk AML characterized by a FLT3-ITD mutation, he
was referred for stem cell transplantation. He has recently under-
gone an allogeneic matched unrelated donor stem cell transplant
using a conditioning regimen of busulfan, fludarabine, clofara-
bine, and anti-thymoglobulin. The patient has achieved successful
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FIGURE 1 | Clinical course.
FIGURE 2 | Computed tomography (CT) scan of head without
intravenous (IV) contrast demonstrating scattered multifocal acute
intra-cerebral hemorrhage (ICH) and marked perilesional edema after
supportive treatment of ICH.
engraftment with 100% chimerism, negative minimal residual
disease and negative FLT3 mutation, and is participating in a post-
stem cell transplant azacitidine maintenance trial. He remains in
complete remission 8 months after his initial diagnosis, without
further complications or recurrence of ICH.
Although APL has the strongest association with DIC, ICH
remains an important cause of early death in all patients with
AML. Both monocytic differentiation and hyperleukocytosis are
independent risk factors for early death associated with this
complication in patients with AML (5).
There is conflicting evidence supporting the early initiation of
rFVIIa in patients with ICH, whereas early initiation of rFVIIa was
associated with shrinkage of the hematoma,reduction in mortality,
and improved functional outcomes at 90 days; it is also associated
with a slightly increased risk of thromboembolic complications
in patients who received higher dose of rFVIIa (80µg/kg), and no
increased risk of thrombosis in patients who received lower dose of
rFVIIa (20µg/kg) compared to placebo (6). However, subsequent
studies have revealed conflicting evidence regarding the effective-
ness of early rFVIIa use, confirming reduced hematoma size in
patients who received rFVIIa but were unable to exhibit reduced
mortality or improved functional outcomes after ICH (7).
There are limited data supporting the clinical role for rFVIIa in
patients with DIC. There are reports of rFVIIa use in DIC patients
with postpartum hemorrhage as well as those with trauma, sep-
sis, or cancer (8). One group has reported a case-series outlining
the successful use of rFVIIa in patients with cancer and DIC-
related bleeding complications (9). Also, Franchini and colleagues
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reported the successful use of rFVIIa in patients with critical
hemato-oncologic bleeding associated with thrombocytopenia
(10). Furthermore, Nosari and colleagues reported on the suc-
cessful use of rFVIIa in an AML patient with ICH (11). Whether
rFVIIa provides significant additional benefits to aggressive trans-
fusion in patients with hematologic malignancies with ICH in the
setting of severe thrombocytopenia and DIC remains unclear.
A recent study demonstrated that the use of rFVIIa for the pre-
vention and treatment of bleeding in patients without hemophilia
resulted in an increased incidence of arterial thromboembolic
events (12). In a large and comprehensive cohort in placebo-
controlled trials of rFVIIa, the risk of arterial thrombosis is asso-
ciated with treatment with high doses of rFVIIa, especially among
the elderly (13). Therefore, the routine use of high dose of rFVIIa
in elderly patients without frequent evaluation of bleeding status
is strongly discouraged.
Treatment of ICH with antifibrinolytic therapy including
tranexamic acid, epsilon aminocaproic acid, or an equivalent
resulted in significant reduction in the risk of re-bleeding in
patients with aneurysmal subarachnoid hemorrhage (14).
It remains unclear whether the use of antifibrinolytic therapy
resulted in shorter time to achieve hemostasis in patients with
severe coagulopathy and thrombocytopenia.
Although current guidelines do not recommend the routine use
of rFVIIa for the treatment of acute ICH (15), this case describes
the safety and feasibility of a one-time administration of rFVIIa
concurrent with continuous aminocaproic acid treatment in AML
patients with life-threatening ICH. The optimal dose of and dos-
ing schedule for rFVIIa are unclear, and further studies of this
agent in patients with hematologic malignancies who experience
life-threatening ICH refractory to aggressive transfusion support
are warranted.
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